Neonatal respiratory distress syndrome (RDS) is caused by inadequate surfactant production within the underdeveloped lung, which may result in atelectesis. Curosurf (poractant alfa) is an intratracheal surfactant suspension indicated for the rescue treatment of premature infants suffering from RDS.